research Hematological ratios in pediatric patients with alopecia areata based on a nationwide retrospective cohort study
Certain blood cell ratios are higher in kids with alopecia areata and might help predict the disease.
Search
for
Sort by
Research
840-870 / 1000+ results
research Hormonal and Immunological Correlations in Alopecia Areata Patients: Focus on Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)
Alopecia areata patients have higher hormone levels, suggesting hormonal screening could help in treatment.
research Development of a Visual Extension of the Severity of Alopecia Tool (VESALT) for Alopecia Areata
VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
research Efficacy of Intralesional Vitamin D in the Treatment of Alopecia Areata Using Dermoscopy before and after Treatment
Intralesional vitamin D is mildly effective for treating Alopecia Areata.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Clinical and demographic factors associated with nail involvement in adult alopecia areata patients at Al-Kadhmia teaching hospital, Baghdad, 2023
Nail changes in alopecia areata are common and may indicate severity and genetic risk.
research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
research Assessment of Nitric Oxide Synthase Protein Level in the Scalp of Androgenetic Alopecia
Higher nitric oxide synthase levels in the scalp may influence hair loss in androgenetic alopecia.
research Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
research Alopecia areata and health-related quality of life: a systematic review and meta-analysis
Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
research The association between androgenic alopecia severity and the development of metabolic syndrome in Saudi Arabia: A case-control study
There's a significant link between severe hair loss and metabolic syndrome in Saudi Arabia, suggesting early health checks could prevent future issues.
research Controlled Evaluation Study of Serum Level of Zinc and Iron in Patients with Androgenetic Alopecia (REVISED)
Female hair loss patients may benefit from zinc and iron supplements.
research Serum level of retinol-binding protein 4 in alopecia areata: relation with recurrence and severity
Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.
research Evaluating The Association of Dyslipidemia with Androgenetic Alopecia among Male Patients
research Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
Alopecia Areata in Saudi Arabia is costly, mainly due to lost work and medication expenses, needing better diagnosis, treatment, and care.
research Serum Adiponectin and Leptin in Patients with Alopecia Areata
Lower adiponectin and higher leptin levels may predict hair loss in alopecia areata.
research Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
Baricitinib is effective and safe for treating severe alopecia areata.
research Serum iron and ferritin levels in alopecia areata
Iron and ferritin levels don't affect alopecia areata.
research 73143 Stem Cell Therapies for Androgenetic Alopecia: A Systematic Review and Single-Arm Meta-analysis
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Evaluation of some biochemical markers in alopecia areata
People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.
research Sub-acute toxicity of standardized aqueous extract of Siddha herb Karisalankanni - Eclipta alba (L.) Hassk
Eclipta alba extract is generally safe with mild liver and kidney changes at high doses.
research Aldesleukin
Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research The assessment of knowledge and awareness about iron deficiency anemia among the population of Riyadh province
More awareness and education on iron deficiency anemia are needed in Riyadh.
research The Relationship Between Depression Levels and Suicide Risk in Pediatric Patients with Alopecia Areata and the Oxidant-Antioxidant Balance
Oxidative stress may play a role in alopecia areata, but depression and suicide risk are similar to healthy peers.
research Complete hair regrowth in a young male with severe atopic dermatitis and alopecia areata after dupilumab: probably more than a coincidence
Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.